Poseidon Medical Inc.
- Industry
- Medical Devices & Equipment
- Founded Year
- 2003
- Headquarters
- Hollywood, Florida, United States
- Employee Count
- 4
Key People
- Horace Davis - Co-CEO
- Carl St. Bernard - Co-CEO
- Richard Davis - Founder & CEO
- Angela Sola - Controller
- John Vacha - Chief Financial Officer
- Barbara Derr - Global Director, Supply Chain
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with over a decade in the medical device industry.
A seasoned team with over ten years in the field brings valuable insights and networks, enhancing the company's ability to execute its strategic plans effectively.
- Clinical Need
-
Aspect: Very Strong
Summary: The Arkrona System addresses a significant unmet need in treating Left Main disease, offering a novel solution where current options are limited.
Left Main disease presents a high-risk scenario with few interventional options. The Arkrona System's design to treat both main and branch vessels could revolutionize care for these patients.
- Competition
-
Aspect: First mover
Summary: Poseidon Medical aims to be the first to market with a device specifically approved for Left Main PCI, potentially establishing a strong competitive advantage.
The absence of direct competitors in the Left Main PCI space allows Poseidon Medical to set industry standards and build strong relationships with healthcare providers.
- Technical Challenge
-
Aspect: Complex
Summary: Developing a two-part drug-eluting device for bifurcation lesions involves significant technical complexities.
Ensuring the device's efficacy and safety necessitates overcoming hurdles in material science, drug delivery mechanisms, and precise deployment techniques.
- Patent
-
Aspect: Very Strong
Summary: With 37 patents, Poseidon Medical demonstrates a robust intellectual property portfolio.
The extensive patent holdings cover various aspects of the Arkrona System, safeguarding against potential infringements and enhancing the company's valuation.
- Financing
-
Aspect: Medium
Summary: The company has raised $126 million over multiple funding rounds, indicating solid financial backing.
The medical device sector demands significant resources for R&D, regulatory approvals, and market entry. Continuous financial support is crucial for sustained progress.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The Arkrona System is undergoing pivotal trials, a critical step toward FDA approval.
Pivotal trials are designed to provide definitive evidence of a device's safety and efficacy. Their outcomes will significantly influence the regulatory pathway and commercialization timeline.
Opportunity Rollup
- Odds of Success
- 3.8
- Peak Market Share
- 5.4
- Segment CAGR
- 4.0%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Interventional Cardiology
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.27 |
| 2 | 0.81 |
| 3 | 1.89 |
| 4 | 3.78 |
| 5 | 5.40 |
Key Takeaway
Poseidon Medical's Arkrona System addresses a critical unmet need in Left Main disease treatment, positioning the company as a potential leader in this niche market, contingent upon successful clinical trials and regulatory approvals.